Advice Pool - Health and Fitness

Diabetes mellitus is defined as a fasting blood glucose of 126 milligrams per deciliter (mg/dL) or more. “Pre-diabetes” is a condition

According to USFDA, a combination product is one composed of any combination of a drug and device; biological product and device; drug and biological product

in which blood glucose levels are higher than normal but not yet diabetic. Diabetes can cause many complications. Acute complications (h

; or drug, device, and biological product and fixed dose combination would include two or more combinations of drug.

Examples of combination products may in

poglycemia, ketoacidosis or nonketotic hyperosmolar coma) may occur if the disease is not adequately controlled. Serious long-term compl

lude drug-coated devices, drugs packaged with delivery devices in medical kits, and drugs and devices packaged separately but intended to be used together.

cations include cardiovascular disease (doubled risk), chronic renal failure (diabetic nephropathy is the main cause of dialysis in deve

here is enormous increase in the number of combination products entering the market in the recent years. Combination products have proven advantages but fixe

oped world adults), retinal damage (which can lead to blindness and is the most significant cause of adult blindness in the non-elderly

d dose combinations are still in the process of convincing regulatory authority on their advantages over the single ingredient formulations.

Combination pro

n the developed world), nerve damage (of several kinds), and microvascular damage, which may cause erectile dysfunction (impotence) and

ucts have become life saving products for the pharmaceutical companies who doesn’t have many innovative molecules in their product pipeline and have been inc

oor healing. Poor healing of wounds, particularly of the feet, can lead to gangrene which can require amputation — the leading cause of

easingly used in the product life cycle management. Even the companies having product patents are trying to extend their product life cycle through the combi

non-traumatic amputation in adults in the developed world.

Diabetes is the third leading cause of death in the United States after hear

nation products and maximize the revenues. But the companies involved in this practice are overlooking that they are burdening the patients both economically

disease and cancer. Over time, diabetes can lead to blindness, kidney failure, and nerve damage. These types of damage are the result o

and physically. They need to rightly judge the benefits of the combination products and they have to even look at the risks involved when combining the produ

damage to small vessels, referred to as microvascular disease. Diabetes is also an important factor in accelerating the hardening and n

ts. Some of the combination products were well accepted by physicians while others suffered. Companies involved in development of combination products are fi

rrowing of the arteries (atherosclerosis), leading to strokes, coronary heart disease, and other large blood vessel diseases. This is re

ding difficulty in defining their combination products and facing various challenges from selecting a combination to marketing it.

Following aspects would a

erred to as macrovascular disease. Diabetes affects approximately 17 million people (about 8% of the population) in the United States. I

dd to the challenges in developing combination products:

Which markets to tap where the combination products can do fairly well?
Which combination prod

addition, an estimated additional 12 million people in the United States have diabetes and don't even know it. Normally, blood glucose

cts are meaningful and rational?
Which therapeutic categories to select?
Which Combinations can address unmet needs of the patients?
Do combin

evels are tightly controlled by insulin, a hormone produced by the pancreas. Insulin lowers the blood glucose level.

Non-insulin-depend

tions increase the patient compliance?
What would be the developing cost?
How to tackle the risks encountered during combination product developmen

ent diabetes mellitus (NIDDM)—is due to a combination of defective insulin secretion and insulin resistance or reduced insulin sensitivi

t?

As combination products don't fit into the traditional categories of drugs, medical devices, or biological products, the USFDA is in the process of devel

y (defective responsiveness of tissues to insulin), which almost certainly involves the insulin receptor in cell membranes. In the early

ping new procedures for reviewing their safety, efficacy and quality.

Professional from academic institutions, pharmaceutical industries, health care indust

stage the predominant abnormality is reduced insulin sensitivity, characterized by elevated levels of insulin in the blood. Gestational

y and representatives from various regulatory agencies are working out to design the regulatory requirements for manufacture and sale of combination products

iabetes also involves a combination of inadequate insulin secretion It develops during pregnancy and may improve or disappear after del

.

As there is an increasing trend of the combination products companies manufacturing such products should be able to tackle the problems involved in the de

very. Even though it may be transient, gestational diabetes may damage the health of the fetus or mother, and about 20%–50% of women wit

elopment. They need to be wiser in analyzing the market trends and the regulatory requirements.

Companies that provide selfless information through particip

gestational diabetes develop type 2 diabetes later in life.Gestational diabetes mellitus (GDM) occurs in about 2%–5% of all pregnancies

tion in industry events and feedback to regulatory authorities would be able to face the challenges and will be successful in developing combination products

HTTP = HTML link (for blogs, profiles,phorums):
<a href="http://www.advicepool.org.ua/article/240255/advicepool-What-is-Diabetes-Mellitus.html">What is Diabetes Mellitus?</a>

BB link (for phorums):
[url=http://www.advicepool.org.ua/article/240255/advicepool-What-is-Diabetes-Mellitus.html]What is Diabetes Mellitus?[/url]

Market Research is the most thing to consider when you put your FSBO (For Sale Owner) home on the market. The price you set will determine how quickly you will sell. But how do you come up with the right price? Here are a few things you might want to consider.

Online personals and dating can be a very fun venue towards meeting that special someone. However, one's safety should still be the top priority. Did you know that most online dating services do not pre-screen their users? This means that they cannot ensure that the people you meet through their sites are safe enough to be dealt with. So, this makes you call the shots when it comes to screening them.

Tags

Links

Advice Pool - What is Diabetes Mellitus?

Related Articles: